重组人生长激素治疗儿童特发性矮小症的疗效及对血清Ghrelin和IGF-1水平的影响

目的:探讨重组人生长激素(rhGH)治疗儿童特发性矮小症(ISS)的疗效及对血清饥饿激素(Ghrelin)、胰岛素样生长因子-1(IGF-1)水平的影响。方法:选取2014年1月-2016年8月期间我院收治的ISS患儿114例为研究对象。按照随机数字表法分为实验组(n=57)与对照组(n=57)。其中对照组给予常规治疗,实验组在对照组基础上联合rhGH治疗,两组疗程均为12个月。比较两组患儿的临床疗效,同时观察并对比两组患儿治疗前后血清Ghrelin以及IGF-1水平。结果:治疗后两组患儿身高、生长速率均较治疗前升高,且实验组高于对照组,差异有统计学意义(P0.05);治疗后两组患儿体重、总甲状腺素、骨龄、空腹血糖水平较治疗前比较差异无统计学意义(P0.05)。治疗后两组患儿血清Ghrelin水平较治疗前降低,且实验组低于对照组,血清IGF-1水平较治疗前升高,且实验组高于对照组,差异均有统计学意义(P0.05)。实验组不良反应发生率为5.26%,与对照组的0.00%比较,差异无统计学意义(P0.05)。结论:ISS患儿应用rhGH治疗效果满意,可明显改善ISS患儿体内血清IGF-1、Ghrelin水平,安全无副作用,促进患儿健康成长。

Clinical Effect of Recombinant Human Growth Hormone in the Treatment of Children with Idiopathic Short Stature and its Effect on Serum Ghrelin and IGF-1 Levels

ABSTRACT Objective: To investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with idiopathic short stature (ISS) and the effects of serum Ghrelin (Ghrelin), insulin-like growth factor -1 (IGF-1) levels. Methods: 114 children with ISS who were treated in our hospital from January 2014 to October 2016 were selected as the research objects. The patients were divided into two groups according to the random number table: the experimental group (n=57) and the control group (n=57). The control group was given conventional treatment, and the experimental group was treated with rhGH on the basis of the control group. The clinical efficacy of the two groups after treatment was compared, the levels of serum Ghrelin and IGF-1 were observed and compared between the two groups before and after treatment. Results: The height and growth rate of the two groups after treatment were higher than before treatment, and the experimental group was higher than that of the control group, the differences were statistically significant (P<0.05). There were no significant differences in weight, total thyroxine, bone age and fasting blood glucose level between the two groups after treatment (P>0.05). The level of Ghrelin in two groups after treatment was lower than that before treatment, and the experimental group was lower than that of the control group, the level of IGF-1 in two groups after treatment was higher than before treatment, and the experimental group was higher than that of the control group, the differences were statistically significant (P<0.05). The incidence of adverse reactions in the experimental group was 5.26%, while that of the control group was 0.00%, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The treatment of rhGH in children with ISS is satisfactory, can significantly improve the serum IGF-1 and Ghrelin levels in children with ISS, safety and no side effects, and promote the healthy growth of children.